Notably, CTGF mRNA expression was significantly lower in cells treated with NAX035 (p < 0.01) and NAX057 (p < 0.001) when compared to the control (Figure 5d), indicating an activation of the tumor-suppressor Hippo pathway after treatment with these BBR analogs. The gene discussed is CCN2; the disease is neoplasm.